Dacomitinib/Dacomitinib Instructions for Use: Correct Usage and Dosage

Dacomitinib/Dacomitinib (Dacomitinib) is a first-line treatment for non-small cell lung cancer with specific gene mutations. When selecting applicable patients, doctors will first detect the EGFR gene in tumor specimens, especially focusing on deletion of exon 19 or L858R substitution mutation on exon 21. Only if the presence of these specific mutations is confirmed will doctors consider dacomitinib as a treatment option for metastatic NSCLC.

Regarding the usage and dosage of dacomitinib, the recommended standard dose is 45 mg orally once a day. Patients can choose to take it with food or on an empty stomach, depending on their individual medication habits and physical condition. It is important that patients continue taking dacomitinib until their disease progresses or until the side effects of the drug become unacceptable.

If adverse reactions occur while taking dacomitinib, the doctor will adjust the drug dosage according to the patient's specific condition. Typically, the initial dose adjustment will be to reduce the dosage to 30 mg orally once daily. If the adverse reaction persists or worsens, the doctor will consider a second dose adjustment, reducing it to 15 mg orally once a day. Such adjustments are intended to ensure that patients continue to receive treatment as tolerated.

In addition, patients should avoid concurrent use of proton pump inhibitors (PPIs) while taking dacomitinib, as these drugs may affect the absorption and effect of dacomitinib. As an alternative, patients may use topically acting antacids to relieve stomach upset. If a histamine 2 (H2) receptor antagonist is indeed necessary, dacomitinib should be taken at least 6 hours before or at least 10 hours after taking the H2 receptor antagonist to ensure that the two drugs do not interfere with each other.